Sarepta Therapeutics (SRPT) Receivables - Other (2011 - 2026)

Sarepta Therapeutics' Receivables - Other history runs 16 years deep, the most recent figure standing at $136.4 million for Q1 2026.

• In Q1 2026, Receivables - Other rose 147.1% year-over-year to $136.4 million; the TTM figure through Mar 2026 stood at $136.4 million (up 147.1% YoY), while the FY2025 annual figure was $104.1 million, up 200.87% from the prior year.
• Receivables - Other was $136.4 million for Q1 2026 at Sarepta Therapeutics, up from $104.1 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $136.4 million in Q1 2026 to a low of $17.7 million in Q1 2022.
• Historically, Receivables - Other has averaged $53.7 million across 5 years, with a median of $35.4 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Receivables - Other surged 522400.0% in 2022, then tumbled 51.45% in 2024.
• A 5-year view of Receivables - Other shows it stood at $41.8 million in 2022, then declined by 28.71% to $29.8 million in 2023, then gained by 16.11% to $34.6 million in 2024, then jumped by 200.87% to $104.1 million in 2025, then surged by 31.03% to $136.4 million in 2026.
• The last three Receivables - Other figures came in at $136.4 million (Q1 2026), $104.1 million (Q4 2025), and $128.7 million (Q3 2025), per Business Quant data.